Evidence map›Paper›PMID 38631841›Full record

ArticleBMJ open2024

Restrictive use of Restraints and Delirium Duration in the Intensive Care Unit (R2D2-ICU): protocol for a French multicentre parallel-group open-label randomised controlled trial.

Romain Sonneville, Camille Couffignal, Florian Sigaud, Virginie Godard, Juliette Audibert, Damien Contou, Adam Celier, Michel Djibre, Julien Schmidt, Pierre Jaquet and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04273360 (Restrictive Use of Restraints and Delirium Duration in ICU), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04273360 nacompletednot on this map

Restrictive Use of Restraints and Delirium Duration in ICU: a Randomized Controlled Trial

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2021 to 2025Enrolled423ConditionsRestraint, Physical, Mechanical VentilationArmsSystematic use group, Restrictive use group
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Romain SonnevilleMédecine Intensive Réanimation, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France romain.sonneville@aphp.fr.ORCID 0000-0003-0245-309X
Camille CouffignalINSERM UMR 1137, IAME, Université Paris Cité, Paris, France.ORCID 0000-0002-5006-6249
Florian SigaudMédecine Intensive Réanimation, Grenoble University Hospital, La Tronche, France.
Virginie GodardEpidemiologie, Biostatistique, Recherche Clinique, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Juliette AudibertService de Réanimation Polyvalente et USC, Hopital Louis Pasteur, Chartres, France.
Damien ContouService de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France.
Adam CelierDépartement R3S, Médecine Intensive Réanimation, Sorbonne Université Pitié-Salpêtrière Hospital, Paris, France.
Michel DjibreMédecine Intensive Réanimation, APHP, Hôpital Tenon, Paris, France.
Julien SchmidtMédecine Intensive Réanimation, Assistance Publique-Hôpitaux de Paris, Bobigny, France.
Pierre JaquetMédecine Intensive Réanimation, Hopital Delafontaine, Saint Denis, France.ORCID 0000-0003-0922-3393
Armand Mekontso DessapMédecine Intensive Réanimation, APHP, Hôpitaux Universitaires Henri Mondor, Créteil, France.ORCID 0000-0001-5961-5577
Claire BourelMédecine Intensive Réanimation, Centre hospitalo-universitaire, Lille, France.
Romane BellotEpidemiologie, Biostatistique, Recherche Clinique, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Carine RoyEpidemiologie, Biostatistique, Recherche Clinique, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Fariza LamaraMédecine Intensive Réanimation, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Fatiha EssardyMédecine Intensive Réanimation, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Jean-François TimsitMédecine Intensive Réanimation, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Renaud CornicEpidemiologie, Biostatistique, Recherche Clinique, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
Lila BouadmaMédecine Intensive Réanimation, APHP.Nord, Hôpital Bichat Claude Bernard, Paris, France.
R2D2-ICU investigators
Université Claude Bernard Lyon 1 · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRCentre Hospitalier Saint-Denis · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Victor Dupouy · FRHôpitaux Universitaires Henri-Mondor · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPhysical restraint (PR) is prescribed in patients receiving invasive mechanical ventilation in the intensive care unit (ICU) to avoid unplanned removal of medical devices. However, it is associated with an increased risk of delirium. We hypothesise that a restrictive use of PR, as compared with a systematic use, could reduce the duration of delirium in ICU patients receiving invasive mechanical ventilation. METHODS AND ANALYSIS: The Restrictive use of Restraints and Delirium Duration in ICU (R2D2-ICU) study is a national multicentric, parallel-group, randomised (1:1) open-label, controlled, superiority trial, which will be conducted in 10 ICUs. A total of 422 adult patients requiring invasive mechanical ventilation for an expected duration of at least 48 hours and eligible for prescription of PR will be randomly allocated within 6 hours from intubation to either the restrictive PR use group or the systematic PR use group, until day 14, ICU discharge or death, whichever comes first. In both groups, PR will consist of the use of wrist straps. The primary endpoint will be delirium or coma-free days, defined as the number of days spent alive in the ICU without coma or delirium within the first 14 days after randomisation. Delirium will be assessed using the Confusion Assessment Method-ICU twice daily. Key secondary endpoints will encompass agitation episodes, opioid, propofol, benzodiazepine and antipsychotic drug exposure during the 14-day intervention period, along with a core outcome set of measures evaluated 90 days postrandomisation. ETHICS AND DISSEMINATION: The R2D2-ICU study has been approved by the Comité de Protection des Personnes (CPP) ILE DE FRANCE III-PARIS (CPP19.09.06.37521) on June 10th, 2019). Participant recruitment started on 25 January 2021. Results will be published in international peer-reviewed medical journals and presented at conferences. TRIAL REGISTRATION NUMBER: NCT04273360.

Indexed as

Antipsychotic AgentsDeliriumPropofolAdultCritical CareEquivalence Trials as TopicHumansIntensive Care UnitsMulticenter Studies as TopicRandomized Controlled Trials as TopicRespiration, ArtificialAntipsychotic AgentsPropofolDelirium & cognitive disordersINTENSIVE & CRITICAL CAREPatient Reported Outcome Measures

Identifiers

PMID38631841
PMCPMC11029382
OpenAlexW4394920603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.